Nothing Special   »   [go: up one dir, main page]

MX2019003722A - Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan. - Google Patents

Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan.

Info

Publication number
MX2019003722A
MX2019003722A MX2019003722A MX2019003722A MX2019003722A MX 2019003722 A MX2019003722 A MX 2019003722A MX 2019003722 A MX2019003722 A MX 2019003722A MX 2019003722 A MX2019003722 A MX 2019003722A MX 2019003722 A MX2019003722 A MX 2019003722A
Authority
MX
Mexico
Prior art keywords
methods
immunogenic compositions
tert
treatment
same
Prior art date
Application number
MX2019003722A
Other languages
English (en)
Inventor
Yan Jian
Weiner David
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2019003722A publication Critical patent/MX2019003722A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente se describen composiciones que comprenden antigenos TERT de consenso optimizados y metodos para tratar el cancer y, en particular, composiciones inmunogenicas que tratan y proporcionan proteccion contra el tumor.
MX2019003722A 2016-09-30 2017-09-29 Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan. MX2019003722A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662402695P 2016-09-30 2016-09-30
US201762468124P 2017-03-07 2017-03-07
PCT/US2017/054519 WO2018064588A2 (en) 2016-09-30 2017-09-29 Tert immunogenic compositions and methods of treatment using the same

Publications (1)

Publication Number Publication Date
MX2019003722A true MX2019003722A (es) 2019-09-26

Family

ID=61760146

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003722A MX2019003722A (es) 2016-09-30 2017-09-29 Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan.

Country Status (9)

Country Link
US (2) US11464841B2 (es)
EP (1) EP3518955A4 (es)
JP (2) JP2019534875A (es)
KR (3) KR20230167445A (es)
CN (1) CN110573173B (es)
AU (2) AU2017336088B2 (es)
CA (1) CA3038889A1 (es)
MX (1) MX2019003722A (es)
WO (1) WO2018064588A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3536703T3 (pl) * 2010-11-12 2021-10-25 The Trustees Of The University Of Pennsylvania Konsensusowe antygeny gruczołu krokowego, kodujące je cząsteczki kwasu nukleinowego i ich zastosowania
CN110121354A (zh) * 2016-08-29 2019-08-13 宾夕法尼亚大学理事会 靶向卵泡刺激素受体(fshr)的最优化的合成共有免疫原性组合物
CA3037682A1 (en) * 2016-09-21 2018-03-29 The Wistar Institute Of Anatomy And Biology Optimized synthetic consensus inmunogenic compositions targeting fibroblast activation protein
CA3122259A1 (en) * 2018-12-05 2020-06-11 Linearx, Inc. Amplicon expression vector vaccines
US20220054611A1 (en) * 2018-12-17 2022-02-24 Immune Design Corp. Pathogen-associated molecular pattern molecules and rna immunogenic compositions and methods of using the compositions for treating cancer
WO2021051065A1 (en) * 2019-09-12 2021-03-18 Inovio Pharmaceuticals, Inc. Tert, wt-1, pmsa immunogenic compositions and methods of treatment using the same
IL292462A (en) * 2019-11-04 2022-06-01 Inovio Pharmaceuticals Inc Combined therapy for the treatment of brain cancer
CA3228663A1 (en) * 2021-08-13 2023-02-16 Inovio Pharmaceuticals, Inc Combination therapy to treat brain cancer
CN118064503B (zh) * 2024-03-08 2024-08-02 上海联衡生物科技有限公司 一种基于端粒酶基因的双基因表达载体及其制备和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002509716A (ja) * 1998-03-31 2002-04-02 ユニバーシティ テクノロジー コーポレイション テロメラーゼ抗原に対する免疫応答を惹起するための方法および組成物
WO2000025813A1 (en) 1998-10-29 2000-05-11 Dana-Farber Cancer Institute CANCER IMMUNOTHERAPHY AND DIAGNOSIS USING UNIVERSAL TUMOR ASSOCIATED ANTIGENS, INCLUDING hTERT
JP2004527449A (ja) 2000-02-15 2004-09-09 リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア テロメラーゼ逆転写酵素を用いる癌を治療するための万能ワクチンと方法
EP1257284A4 (en) * 2000-02-15 2005-12-21 Univ California UNIVERSAL VACCINE AND METHOD OF TREATING CANCER USING TELOMERASE REVERSE TRANSCRIPTASE
CA2490863A1 (en) * 2002-06-27 2004-01-08 Geron Corporation Cancer vaccine containing cross-species epitopes of telomerase reverse transcriptase
EP1748067A1 (en) 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
EP3907232B1 (en) 2006-07-28 2024-02-21 The Trustees of the University of Pennsylvania Improved hiv vaccines
JP2010505433A (ja) * 2006-10-12 2010-02-25 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー テロメラーゼ逆転写酵素融合タンパク質、これをコードするヌクレオチドおよびこれの用途
US10206997B2 (en) * 2011-11-10 2019-02-19 Bin Wang Facilitator-DNA combination vaccine
AU2014228405B2 (en) * 2013-03-15 2017-05-11 The Trustees Of The University Of Pennsylvania Cancer vaccines and methods of treatment using the same
EP2871235A1 (en) * 2013-11-07 2015-05-13 Centre National de la Recherche Scientifique (CNRS) New methods to produce active hTERT
CA3037682A1 (en) * 2016-09-21 2018-03-29 The Wistar Institute Of Anatomy And Biology Optimized synthetic consensus inmunogenic compositions targeting fibroblast activation protein
WO2018204760A1 (en) 2017-05-05 2018-11-08 David Weiner Ctla4 antibodies and vaccine combinations and use of same for immunotherapy

Also Published As

Publication number Publication date
AU2017336088B2 (en) 2023-07-06
KR20230167445A (ko) 2023-12-08
KR20220024974A (ko) 2022-03-03
WO2018064588A3 (en) 2018-05-03
WO2018064588A2 (en) 2018-04-05
KR20190120743A (ko) 2019-10-24
US20230115179A1 (en) 2023-04-13
CN110573173A (zh) 2019-12-13
AU2023237174A1 (en) 2023-10-26
JP2019534875A (ja) 2019-12-05
US11464841B2 (en) 2022-10-11
EP3518955A2 (en) 2019-08-07
JP2022179497A (ja) 2022-12-02
US20200030426A1 (en) 2020-01-30
CN110573173B (zh) 2024-11-08
EP3518955A4 (en) 2020-10-07
AU2017336088A1 (en) 2019-05-02
KR102375328B1 (ko) 2022-03-21
CA3038889A1 (en) 2018-04-05

Similar Documents

Publication Publication Date Title
MX2019003722A (es) Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan.
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
PH12020551923A1 (en) Methods and compositions for treating cancer
IL287643A (en) Preparations and methods for treating cancer using tet2 transgenic t cell therapy
MX2018011114A (es) Métodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatías.
EA201890961A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
MX2021013837A (es) Enfoque de inmunoterapias de combinacion para el tratamiento del cancer.
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
ZA201905222B (en) Combination treating prostate cancer, pharmaceutical composition and treatment method
GB2557123A (en) Modified cells and methods of therapy
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
MX2016007351A (es) Terapia de combinacion para tratar cancer.
MX2021006734A (es) Metodo para tratar el cancer.
MX2018001755A (es) Vacuna contra viruela para tratamiento del cancer.
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
MD20170073A2 (ro) Terapii combinate pentru tratarea cancerelor
MX2019011148A (es) Metodos de tratamiento.
EP4252851A3 (en) Ezh2 inhibitors for treating lymphoma
MX2017013142A (es) Terapia combinada para tratar cáncer.
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
EA201890957A1 (ru) Комбинированная терапия для лечения злокачественных опухолей
MX2017012824A (es) Tratamiento de cáncer de pulmón con inhibidores de glutaminasa.
WO2017139570A8 (en) Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccine